Spanish clinical study demonstrates mariPOC’s excellent performance
ArcDia International Ltd announces that a new independent, peer-reviewed clinical study demonstrates the excellent performance of the mariPOC® Respi test for influenza-like illnesses.
A recent study demonstrates that treatment of influenza-like illnesses can be significantly improved by using the new mariPOC® rapid tests. Until now, only central laboratories have been able to provide results with sufficient accuracy. The long time to results and the high cost of the tests have meant that physicians have only been able to give the most critically ill patients an exact diagnosis. mariPOC® is the first test to make reliable results directly available at the physician’s office or clinic.
The test covers 10 pathogens from a single sample. With it, physicians are able to provide immediate treatment for the most common infections in the world. It is expected that this development will streamline healthcare and save costs; but, most importantly of all, it will provide better care for patients.
Dr Sanbonmatsu-Gámez compared the mariPOC® test to central laboratory genetic testing based on nucleic acid amplification and concluded that: ‘The good analytical performance and extended portfolio of mariPOC show this rapid assay as a good alternative for the etiological diagnosis of acute respiratory infection in laboratories that are not equipped with molecular assays.’ The authors also concluded that the advantage of mariPOC® over other rapid tests is multiplexing that allows simultaneous detection of those viruses, such as influenza and RSV, that have a major impact on health systems. Eighty-five per cent of positive patients samples were reported as positive by mariPOC® in 20 minutes, which is today an industry record formultiplexed detection of flu-like illnesses.
“These performance figures are excellent, because central laboratory PCR genetic tests have become even too sensitive: PCR is known to sometimes report analytically false positives and to be prone to report clinically irrelevant findings, says Dr. Janne Koskinen, Director of R&D at ArcDia.
“In this study, the analytical specificities of the mariPOC® test were 99.7 % on average. This is significantly better than that reported for PCR-based methods. High specificity means that a positive result is a reliable indicator of infection. It is all coming together now: the physician gets the result he or she needs; when he needs it and at a cost lower than before”, says Dr Koskinen.
The value of ArcDia’s mariPOC® product line has already attracted worldwide attention. In 2014, Frost & Sullivan granted the “Point-of-Care Product Leadership Award” to mariPOC®.
Dr Koskinen continues: “mariPOC® is a welcome new tool for first-line diagnostics, as this study and the Frost & Sullivan award shows. Simply put, the mariPOC® tests enable physicians to provide us all with better treatment.
The clinical study performed in Spain by Dr Sanbonmatsu-Gámez et al. is published in the November issue of the journal Diagnostic Microbiology and Infectious Disease (Vol. 83: Issue 3, p. 252–256).
mariPOC® provides multianalyte diagnostic results for influenza-like illnesses and tonsillitis in near-patient settings in 20 minutes. The mariPOC® applications are targeted at acute respiratory infections, the most common infectious disease on Earth. mariPOC® is designed to improve patient management and quality of healthcare, and it allows timely pathogenspecific diagnostics and medication.
ArcDia International Ltd, located in Turku Science Park area, is the manufacturer of mariPOC®, the world’s first multianalyte point-of-care diagnostics test for respiratory tract infections. The company plans to develop additional point-of-care tests based on its proprietary ArcDia™ TPX detection technology.